1. In Vivo
  2. >>Deal-Making

Investing In Digital: Slow And Steady May Win This Race

 
• By Barnaby Pickering

Getting out the gates early is usually the playbook for VC, however when it comes to new technologies with untested commercial pipelines, waiting and seeing may be a smarter approach.  

A “slow and steady wins the race” mindset is not one usually seen in venture finance. 

Typically, funds want to deploy cash quickly, see results and make an exit – oftentimes within five years.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.